Published in Curr Signal Transduct Ther on May 01, 2009
The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance. J Steroid Biochem Mol Biol (2012) 0.98
New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. Breast (2009) 0.94
The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities. Breast (2011) 0.86
Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance. Int J Oncol (2010) 0.85
Synthetic progestins differentially promote or prevent 7,12-dimethylbenz(a)anthracene-induced mammary tumors in sprague-dawley rats. Cancer Prev Res (Phila) (2010) 0.82
Molecular modulation of estrogen-induced apoptosis by synthetic progestins in hormone replacement therapy: an insight into the women's health initiative study. Cancer Res (2014) 0.82
Triple-negative breast cancer risk in women is defined by the defect of estrogen signaling: preventive and therapeutic implications. Onco Targets Ther (2014) 0.80
Overexpression of truncated AIF regulated by Egr1 promoter radiation-induced apoptosis on MCF-7 cells. Radiat Environ Biophys (2015) 0.78
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
The steroid and thyroid hormone receptor superfamily. Science (1988) 25.68
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 22.10
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet (2005) 11.05
Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A (1996) 10.94
The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell (1998) 9.96
Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (1997) 9.09
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet (1999) 7.72
Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science (2004) 7.63
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res (2006) 7.18
Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst (1999) 6.60
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst (2004) 6.55
Functional domains of the human estrogen receptor. Cell (1987) 6.52
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat (2008) 4.84
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc Natl Acad Sci U S A (1966) 4.73
The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ (2003) 4.72
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst (2003) 4.45
Sequence and expression of human estrogen receptor complementary DNA. Science (1986) 4.36
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst (2005) 4.25
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 4.09
Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol (2000) 3.96
Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst (2001) 3.88
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 3.84
Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A (2000) 3.69
The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology (1999) 3.67
The importance of glutathione in human disease. Biomed Pharmacother (2003) 3.61
The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol Cell (2000) 3.23
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev (2008) 3.13
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst (2003) 3.09
Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov (2003) 3.07
Synthetic oestrogens in mammary cancer. Lancet (1949) 3.06
Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol (2006) 2.90
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A (2006) 2.86
Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ (2006) 2.85
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol (2006) 2.85
Identification of two transactivation domains in the mouse oestrogen receptor. Nucleic Acids Res (1989) 2.70
Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res (2004) 2.67
A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res (1993) 2.65
Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact (1998) 2.55
Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res (2003) 2.43
Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst (2003) 2.18
Estrogen receptor phosphorylation. Steroids (2003) 2.17
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol (2005) 2.12
Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst (2005) 2.10
Influence of Synthetic Oestrogens on Advanced Malignant Disease. Br Med J (1944) 2.06
Minireview: nuclear receptor coactivators--an update. Endocrinology (2002) 2.04
Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol (2007) 2.02
Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem (2000) 2.00
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol (2005) 1.99
The estrogen receptor: a model for molecular medicine. Clin Cancer Res (2003) 1.99
BCL-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity. Free Radic Biol Med (1999) 1.95
A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil (1967) 1.94
Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol Metab (2005) 1.93
Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell (2004) 1.92
Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst (2003) 1.92
Estrogen receptor interaction with co-activators and co-repressors. Steroids (2000) 1.91
Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids (2006) 1.89
High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat (2001) 1.88
Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst (1991) 1.84
Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res (1988) 1.80
Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res (1990) 1.78
Biochemical pharmacology of antiestrogen action. Pharmacol Rev (1984) 1.74
Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res (2000) 1.73
Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res (2007) 1.71
Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat (1987) 1.70
Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med (1981) 1.70
Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol (1992) 1.65
Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther (2005) 1.60
Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res (1987) 1.52
Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer (2008) 1.50
Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst (2002) 1.50
Minireview: estrogen receptor-mediated rapid signaling. Endocrinology (2006) 1.49
Targeting the EGFR pathway for cancer therapy. Curr Med Chem (2006) 1.48
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer (2007) 1.47
Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc Natl Acad Sci U S A (1999) 1.46
Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res (1988) 1.44
Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene (2003) 1.43
Diversity in the mechanisms of gene regulation by estrogen receptors. Bioessays (2002) 1.43
A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol. Endocrinology (1958) 1.37
Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst (1997) 1.35
Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol (2005) 1.31
Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat (2006) 1.29
Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother (2006) 1.28
Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res (2006) 1.27
A membrane-targeted BID BCL-2 homology 3 peptide is sufficient for high potency activation of BAX in vitro. J Biol Chem (2006) 1.26
Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res (2007) 1.24
Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemother Pharmacol (2005) 1.24
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res (2006) 1.24
Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02. Clin Cancer Res (2007) 1.22
Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics (1993) 1.22
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) (2010) 5.81
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst (2003) 2.18
International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev (2006) 2.15
Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst (2005) 2.10
Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem (2006) 2.03
The estrogen receptor: a model for molecular medicine. Clin Cancer Res (2003) 1.99
The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J Biol Chem (2005) 1.96
Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst (2003) 1.92
Differential DNase I hypersensitivity reveals factor-dependent chromatin dynamics. Genome Res (2012) 1.85
Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer (2004) 1.82
Early breast cancer. Lancet (2009) 1.82
Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res (2009) 1.75
Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A (2009) 1.75
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol (2012) 1.71
Most plastic products release estrogenic chemicals: a potential health problem that can be solved. Environ Health Perspect (2011) 1.63
Estrogen receptor expression and sensitivity to paclitaxel in breast cancer. Cancer Biol Ther (2004) 1.63
The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol (2004) 1.55
Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res (2005) 1.50
Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst (2002) 1.50
The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol (2013) 1.44
Estrogen-related receptors as emerging targets in cancer and metabolic disorders. Curr Top Med Chem (2006) 1.39
The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res (2010) 1.36
Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway. Mol Cancer Res (2007) 1.36
Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci U S A (2011) 1.33
Protective effects of dietary antioxidants on proton total-body irradiation-mediated hematopoietic cell and animal survival. Radiat Res (2009) 1.31
Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res (2006) 1.23
Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs). Breast Dis (2006) 1.22
Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Clin Cancer Res (2008) 1.18
MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions. J Biol Chem (2003) 1.15
3-Methylcholanthrene and other aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha. Cancer Res (2006) 1.14
Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis. Breast Cancer Res (2008) 1.14
Progress in endocrine approaches to the treatment and prevention of breast cancer. Maturitas (2011) 1.11
Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha. Int J Cancer (2003) 1.11
Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anticancer Agents Med Chem (2009) 1.09
c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells. Cancer Res (2013) 1.09
Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. J Steroid Biochem Mol Biol (2005) 1.09
Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Int J Oncol (2009) 1.08
Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA. Breast Cancer Res (2015) 1.08
Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J Biol Chem (2004) 1.07
Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach? Eur J Cancer (2009) 1.07
Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen. J Med Chem (2010) 1.05
Steroid receptors and their role in the biology and control of breast cancer growth. Semin Oncol (2006) 1.05
Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. Clin Breast Cancer (2008) 1.05
The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol (2002) 1.04
Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res (2002) 1.04
The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1. Mol Pharmacol (2011) 1.04
Estrogen regulation of X-box binding protein-1 and its role in estrogen induced growth of breast and endometrial cancer cells. Horm Mol Biol Clin Investig (2010) 1.03
Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. J Biol Chem (2002) 1.03
Selective estrogen receptor modulators and phytoestrogens. Planta Med (2008) 1.02
Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. Mol Cancer Ther (2007) 1.01
Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. Menopause (2013) 1.00
Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells. Eur J Cancer (2008) 0.99
SERMs for the treatment and prevention of breast cancer. Rev Endocr Metab Disord (2007) 0.99
Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. Trends Mol Med (2002) 0.98
Characteristics of salivary profiles of oestradiol and progesterone in premenopausal women. J Endocrinol (2005) 0.97
Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Adv Exp Med Biol (2008) 0.97
MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis. Cancer Res (2005) 0.95
New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. Breast (2009) 0.94
Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2. J Steroid Biochem Mol Biol (2004) 0.94
Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines. Eur J Cancer (2012) 0.94
Bioluminescence imaging for assessment and normalization in transfected cell arrays. Biotechnol Bioeng (2007) 0.94
Aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha in MCF-7 breast cancer cells. Biol Chem (2006) 0.93
Proteomic analysis of pathways involved in estrogen-induced growth and apoptosis of breast cancer cells. PLoS One (2011) 0.93
In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer. Breast Cancer (2002) 0.92
Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations. Horm Mol Biol Clin Investig (2012) 0.92
A prospective study of variability in mammographic density during the menstrual cycle. Breast Cancer Res Treat (2009) 0.90
Interaction of the aryl hydrocarbon receptor ligand 6-methyl-1,3,8-trichlorodibenzofuran with estrogen receptor alpha. Cancer Res (2004) 0.89
Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Eur J Cancer (2010) 0.89
By looking back we can see the way forward: enhancing the gains achieved with antihormone therapy. Breast Cancer Res (2008) 0.88
Is tamoxifen the Rosetta stone for breast cancer? J Natl Cancer Inst (2003) 0.88
Distinct molecular conformations of the estrogen receptor alpha complex exploited by environmental estrogens. Cancer Res (2003) 0.87
Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells. Int J Oncol (2006) 0.87
The consequences of exhaustive antiestrogen therapy in breast cancer: estrogen-induced tumor cell death. Exp Biol Med (Maywood) (2004) 0.87
5,6-Epoxy-cholesterols contribute to the anticancer pharmacology of tamoxifen in breast cancer cells. Biochem Pharmacol (2013) 0.86
Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. Int J Oncol (2007) 0.86
Chemoprevention of breast cancer: current and future prospects. Cancer Metastasis Rev (2002) 0.85
Defining the conformation of the estrogen receptor complex that controls estrogen-induced apoptosis in breast cancer. Mol Pharmacol (2014) 0.85
Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance. Int J Oncol (2010) 0.85
Optimizing the antihormonal treatment and prevention of breast cancer. Breast Cancer (2007) 0.85
Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clin Cancer Res (2006) 0.85
Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant. J Steroid Biochem Mol Biol (2006) 0.84
Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells. J Biol Chem (2001) 0.84
Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story. Vitam Horm (2013) 0.83
Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G0/G1 cell cycle arrest in SKBr3 breast cancer cells. Int J Oncol (2010) 0.83
Retracted Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. Expert Opin Pharmacother (2011) 0.83
Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst (2003) 0.83
A mechanism of drug resistance to tamoxifen in breast cancer. J Steroid Biochem Mol Biol (2002) 0.83
Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers. Breast Cancer Res Treat (2013) 0.82
Role of the progesterone receptor (PR) in susceptibility of mouse mammary gland to 7,12-dimethylbenz[a]anthracene-induced hormone-independent preneoplastic lesions in vitro. Cancer Lett (2002) 0.82
Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes. Br J Pharmacol (2014) 0.82
Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement. Breast Cancer Res Treat (2015) 0.82
Chemoprevention of breast cancer: a model for change. J Clin Oncol (2002) 0.82
Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. Clin Cancer Res (2002) 0.82
Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer. J Steroid Biochem Mol Biol (2009) 0.82
The Conformation of the Estrogen Receptor Directs Estrogen-Induced Apoptosis in Breast Cancer: A Hypothesis. Horm Mol Biol Clin Investig (2011) 0.81